-
Ablaze Pharma to Invest $100M in Chengdu TRT R&D and Manufacturing Hub
•
Shanghai-based Ablaze Pharma announced plans to invest an initial $100 million in a new research and development and manufacturing center for targeted radiation therapies (TRTs) in Chengdu’s Wenjiang district. The project follows an agreement with the local government and aims to leverage Sichuan’s nuclear science expertise. Project DetailsThe 26,000㎡ facility…
-
Astellas Pharma Posts 17% Q1 Sales Growth Driven by Xtandi and Padcev
•
Japan-based Astellas Pharma Inc. (TYO: 4503) reported a 17.1% year-on-year (YOY) increase in global sales revenues to JPY 381.79 billion (USD 2.89 billion) for the fiscal Q1 period ending June 30, 2022. The growth was driven by strong performance from key oncology and nephrology products. Core Product Highlights Regional GrowthGreater…
-
Eli Lilly’s Taltz Wins Second NMPA Approval for Ankylosing Spondylitis
•
U.S. pharmaceutical giant Eli Lilly announced it has received a second marketing approval from the National Medical Products Administration (NMPA) for Taltz (ixekizumab). The IL-17A monoclonal antibody (mAb) is now approved to treat active ankylosing spondylitis (AS) in patients with a poor response to conventional therapy. Drug BackgroundTaltz was first…
-
China Resources Double-Crane to Acquire Stake in Shenzhou Biotech for Bio-Fermentation Push
•
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced plans to acquire a 50.11% stake in Shenzhou Biotechnology Co., Ltd for RMB 501.73 million (USD 74.1 million). The move aims to expand the firm’s presence in the bio-fermentation sector. Transaction DetailsThe acquisition will give Double-Crane a controlling interest in Shenzhou…
-
Coherent Biopharma Raises Series B Funds to Advance Bi-XDC Pipeline
•
Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), has reportedly raised an undisclosed amount in a Series B financing round. The funding was led by HM Capital and included participation from Suzhou Yuanfeng Capital, ABC International, V-Capital, and existing investor 6 Dimensions Capital. Company ProfileCoherent Biopharma leverages…
-
Hengrui Medicine’s Pyrotinib Combo Meets Endpoints in HER2+ Breast Cancer Trial
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its tyrosine kinase inhibitor (TKI) pyrotinib, combined with trastuzumab and docetaxel, met endpoints in a Phase III clinical trial as a first-line treatment for HER2-positive recurrent/metastatic breast cancer. The company plans to hold pre-market approval filing discussions with regulators soon. Study…
-
Shouyao Holdings Receives Approval for CT-3505 ALK Inhibitor Study in NSCLC
•
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced it has received ethical approval from the Cancer Institute and Hospital at the Chinese Academy of Military Science to conduct a Phase I/II clinical study (CT-3505-I-01) of its CT-3505 in patients with ALK-positive non-small cell lung cancer (NSCLC). Drug ProfileCT-3505, an…
-
InnoCare Pharma Doses First Patient in ICP-488 Study for Autoimmune Diseases
•
China-based InnoCare Pharma (HKG: 9969) announced that the first subject has been dosed in a clinical study for ICP-488, its TYK2 JH2 allosteric inhibitor. The drug is being developed for autoimmune diseases such as psoriasis and inflammatory bowel disease (IBD). Mechanism of ActionICP-488 is a potent and selective inhibitor of…
